Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 5

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells

Wei, Chaogang, Wang, Fengjiao, Liu, Wei, Zhao, Wenlu, Yang, Yi, Li, Kai, Xiao, Li, Shen, Junkang · 2017 · Molecular Medicine Reports

Abstract

Androgens have been recognized to be primary causative agents of prostate cancer. Following binding to the androgen receptor (AR), androgens serve important roles in the carcinogenesis of prostate cancers. ARs serve an important role during all stages of prostate cancer, and inhibiting their function may help to slow prostate cancer growth. In the present study, the AR gene was targeted in androgen‑positive prostate cancer cells using the clustered regularly interspaced short palindromic repeats‑associated protein (CRISPR/Cas) system. A total of three different single‑guide RNAs (sgRNAs) were designed according to the three different target sites in the AR gene. The optimal sgRNA with a specific target effect was effectively screened to cleave the AR gene in androgen‑positive prostate cancer cell lines, and to suppress the growth of androgen‑sensitive prostate cancer in vitro. The AR‑sgRNA‑guided CRISPR/Cas system was able to disrupt the AR at specific sites and inhibit the growth of androgen‑sensitive prostate cancer cells; further studies demonstrated that the decreased cell proliferation was due to cellular apoptosis. The results of the present study suggested that the CRISPR/Cas system may be a useful therapeutic strategy for the treatment of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mmr.2017.8257

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Sequencing diagrams of three sgRNAs. (A) sgRNA-AR230, CATTTCCGAAGACGACAAGA; (B) sgRNA-AR231, TGTCCAGCACACACTACACC; (C) sgRNA-AR232, GCACTATTGATAAATTCCGA. The red underlined sections refer to sequences of the three sgRNAs. sgRNA, single-guide RNA.
Figure 1. Sequencing diagrams of three sgRNAs. (A) sgRNA-AR230, CATTTCCGAAGACGACAAGA; (B) sgRNA-AR231, TGTCCAGCACACACTACACC; (C) sgRNA-AR232, GCACTATTGATAAATTCCGA. The red underlined sections refer to sequences of the three sgRNAs. sgRNA, single-guide RNA.CC BY-NC-ND · PubMed Central
Figure 2. Enzymatic electrophoresis of three target sites determined using T7E1 endonuclease. (A) Images of agarose gel demonstrating that the correct fragments of the three different androgen receptor target sites relevant to LV-230, LV-231 and LV-232 were amplified. Lanes M1, M2, and M3 exhibit the amplified products at the expected sizes (LV230, 983 bp; LV231, 702 bp; and LV-232, 983 bp). The two NC lanes exhibit the corresponding products in the NC groups. The same primers were used in lanes M1 and M3 and, therefore, the NC was shared. (B) Agarose gel image exhibiting the mismatch-associated short fragments in the M1 lane, indicating the gene-editing effect of the single-guide RNA-associated clustered regularly interspaced short palindromic repeats-associated protein system. No such obvious gene editing effect was detected in the M2 and M3 lanes. NC, negative control.
Figure 2. Enzymatic electrophoresis of three target sites determined using T7E1 endonuclease. (A) Images of agarose gel demonstrating that the correct fragments of the three different androgen receptor target sites relevant to LV-230, LV-231 and LV-232 were amplified. Lanes M1, M2, and M3 exhibit the amplified products at the expected sizes (LV230, 983 bp; LV231, 702 bp; and LV-232, 983 bp). The two NC lanes exhibit the corresponding products in the NC groups. The same primers were used in lanes M1 and M3 and, therefore, the NC was shared. (B) Agarose gel image exhibiting the mismatch-associated short fragments in the M1 lane, indicating the gene-editing effect of the single-guide RNA-associated clustered regularly interspaced short palindromic repeats-associated protein system. No such obvious gene editing effect was detected in the M2 and M3 lanes. NC, negative control.CC BY-NC-ND · PubMed Central
Figure 3. Proliferation of LNCaP prostate cancer cells. The Cell Counting kit-8 assay demonstrated that knocking down the androgen receptor using the clustered regularly interspaced short palindromic repeats-associated protein system inhibited prostate cancer cell proliferation. Treatment, LNCaP-Cas9-single-guide RNA-AR230; Control, LNCaP-Cas9-control. OD, optical density.
Figure 3. Proliferation of LNCaP prostate cancer cells. The Cell Counting kit-8 assay demonstrated that knocking down the androgen receptor using the clustered regularly interspaced short palindromic repeats-associated protein system inhibited prostate cancer cell proliferation. Treatment, LNCaP-Cas9-single-guide RNA-AR230; Control, LNCaP-Cas9-control. OD, optical density.CC BY-NC-ND · PubMed Central
Figure 4. LNCaP cell proliferation 24 and 72 h post-transfection, demonstrated using green fluorescence microscopy. The images illustrate LNCaP cell growth status 24 h subsequent to the (A) LV-Cas9-sgRNA-AR230 and (B) LV-Cas9-control virus transfection; and LNCaP cell growth status 72 h following the (C) LV-Cas9-sgRNA-AR230 and (D) LV-Cas9-control virus transfection. sgRNA, single-guide RNA.
Figure 4. LNCaP cell proliferation 24 and 72 h post-transfection, demonstrated using green fluorescence microscopy. The images illustrate LNCaP cell growth status 24 h subsequent to the (A) LV-Cas9-sgRNA-AR230 and (B) LV-Cas9-control virus transfection; and LNCaP cell growth status 72 h following the (C) LV-Cas9-sgRNA-AR230 and (D) LV-Cas9-control virus transfection. sgRNA, single-guide RNA.CC BY-NC-ND · PubMed Central
Figure 5. Analysis of cellular apoptosis using flow cytometry. Virus-infected LNCaP cells were stained using Annexin V-APC and 7-AAD. Apoptotic cells and necrotic cells are presented for (A) experimental and (B) control cells. Cells were divided into four regions (Q1-Q4). Region Q1 is representative of mechanical error; region Q2 is representative of late apoptotic and necrotic cells; region Q3 is representative of early apoptotic cells; and region Q4 is representative of living cells. (C) The percentage of early apoptotic cells in the experimental group (LNCaP-Cas9-sgRNA-AR230) and the control group (LNCaP-Cas9-control; *P<0.05). 7-AAD, 7-amino-actinomycin D; APC, allophycocyanin.
Figure 5. Analysis of cellular apoptosis using flow cytometry. Virus-infected LNCaP cells were stained using Annexin V-APC and 7-AAD. Apoptotic cells and necrotic cells are presented for (A) experimental and (B) control cells. Cells were divided into four regions (Q1-Q4). Region Q1 is representative of mechanical error; region Q2 is representative of late apoptotic and necrotic cells; region Q3 is representative of early apoptotic cells; and region Q4 is representative of living cells. (C) The percentage of early apoptotic cells in the experimental group (LNCaP-Cas9-sgRNA-AR230) and the control group (LNCaP-Cas9-control; *P<0.05). 7-AAD, 7-amino-actinomycin D; APC, allophycocyanin.CC BY-NC-ND · PubMed Central
Figure 6. Analysis of the cell cycle using flow cytometry. The DNA profile was analysed using propidium iodide staining and flow cytometry. The percentage of cellular apoptosis is calculated using the percentage of the sub-G1 peak. (A) The LNCaP-Cas9-sgRNA-AR230 cells exhibited high numbers of cells in the sub-G1 peak. (B) The LNCaP-Cas9-control cell samples displayed a low sub-G1 peak. Arrows, sub-G1 peak. (C) The proportions of cells in apoptotic sub-G1 phase from the experimental group (LNCaP-Cas9-sgRNA-AR230) and the control group (LNCaP-Cas9-control; *P<0.05).
Figure 6. Analysis of the cell cycle using flow cytometry. The DNA profile was analysed using propidium iodide staining and flow cytometry. The percentage of cellular apoptosis is calculated using the percentage of the sub-G1 peak. (A) The LNCaP-Cas9-sgRNA-AR230 cells exhibited high numbers of cells in the sub-G1 peak. (B) The LNCaP-Cas9-control cell samples displayed a low sub-G1 peak. Arrows, sub-G1 peak. (C) The proportions of cells in apoptotic sub-G1 phase from the experimental group (LNCaP-Cas9-sgRNA-AR230) and the control group (LNCaP-Cas9-control; *P<0.05).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 19

  1. DeSantis, 2016, Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities, CA Cancer J Clin, 66, 290, 10.3322/caac.21340 · DOI · Paper page
  2. Feldman, 2001, The development of androgen-independent prostate cancer, Nat Rev Cancer, 1, 34, 10.1038/35094009 · DOI · Paper page
  3. Saraon, 2011, Molecular alterations during progression of prostate cancer to androgen independence, Clin Chem, 57, 1366, 10.1373/clinchem.2011.165977 · DOI
  4. Yuan, 2009, Mechanisms mediating androgen receptor reactivation after castration, Urol Oncol, 27, 36, 10.1016/j.urolonc.2008.03.021 · DOI · Paper page
  5. Cohen, 2009, Mechanisms of prostate cancer cell survival after inhibition of AR expression, J Cell Biochem, 106, 363, 10.1002/jcb.22022 · DOI
  6. Horii, 2014, Genome engineering using the CRISPR/Cas system, World J Med Genet, 4, 69, 10.5496/wjmg.v4.i3.69 · DOI · Paper page
  7. Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
  8. Pu, 2015, Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification, Exp Biol Med (Maywood), 240, 1065, 10.1177/1535370215584932 · DOI
  9. Seeger, 2014, Targeting hepatitis B virus with CRISPR/Cas9, Mol Ther Nucleic Acids, 3, e216, 10.1038/mtna.2014.68 · DOI · Paper page
  10. Lu, 2015, Modeling cancer processes with CRISPR-Cas9, Trends Biotechnol, 33, 317, 10.1016/j.tibtech.2015.03.007 · DOI
  11. Tang, 2016, CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: A personalized molecular surgical therapy, EMBO Mol Med, 8, 83, 10.15252/emmm.201506006 · DOI
  12. Wang, 2016, CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape, Mol Ther, 24, 522, 10.1038/mt.2016.24 · DOI · Paper page
  13. Kawamura, 2015, CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells, Oncotarget, 6, 22361, 10.18632/oncotarget.4293 · DOI · Paper page
  14. Zhang, 2006, Efflux of potassium ion is an important reason of HL-60 cells apoptosis induced by tachyplesin, Acta Pharmacol Sin, 27, 1367, 10.1111/j.1745-7254.2006.00377.x · doi:10.1111/j.1745-7254.2006.00377.x
  15. Shore, 2014, Management of early-stage prostate cancer, Am J Manag Care, 20, S260
  16. Yu, 2014, Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells, Onco Targets Ther, 8, 37
  17. Hu, 2014, Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells, Biomed Res Int 2014, 612823
  18. Ding, 2013, Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs, Cell Stem Cell, 12, 393, 10.1016/j.stem.2013.03.006 · DOI · Paper page
  19. Pattanayak, 2014, Determining the specificities of TALENs, Cas9, and other genome editing enzymes, Methods Enzymol, 546, 47, 10.1016/B978-0-12-801185-0.00003-9 · DOI

Cited by

See all 5

Metadata

Authors
Wei, C., Wang, F., Liu, W., Zhao, W., Yang, Y., Li, K., Xiao, L., & Shen, J.
Affiliations
  • Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
  • Department of Pharmacy, The Affiliated Children's Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
  • Center of Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Venue
Molecular Medicine Reports
Published
2017-12-12
ISSN
  • 1791-2997
  • 1791-3004
Cited by
5
References
2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. https://app.cochat.ai/papers/10.3892/mmr.2017.8257
The paper
Wei, C., Wang, F., Liu, W., Zhao, W., Yang, Y., Li, K., Xiao, L., & Shen, J. (2017). CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2017.8257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.